Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. While some 22 patients exhibit bone lesions at single sites, most patients develop chronically active or 23 recurrent bone inflammation at multiple sites, and are then diagnosed with recurrent multifocal 24 osteomyelitis (CRMO). Chronic multifocal osteomyelitis (CMO) mice develop IL-1β-driven 25 sterile bone lesions reminscent of severe CRMO. Mechanistically, CMO disease arises due to 26 loss of PSTPIP2, a negative regulator of macrophages, osteoclasts and neutrophils. The goal 27 of this study was to evaluate the potential involvement of mast cells in CMO/CRMO disease 28 pathophysiology. Here, we show that mast cells accumulate in the inflamed tissues from CMO 29 mice, and mast cell protease Mcpt1 was detected in the peripheral blood. The role of mast cells 30 in CMO disease was investigated using a transgenic model of connective tissue mast cell 31 depletion (Mcpt5-Cre:Rosa26-Stop fl/fl -DTa) that was crossed with CMO mice. The resulting 32 CMO/MC-mice showed a significant delay in disease onset compared to age-matched CMO 33 mice. At 5-6 months of age, CMO/MC-mice had fewer bone lesions and immune infiltration 34 in the popliteal lymph nodes that drain the affected tail and paw tissues. To test the relevance 35 of mast cells to human CRMO, we tested serum samples from a cohort of healthy controls or 36 CRMO patients at diagnosis. Interestingly, mast cell chymase was elevated in CRMO patients 37 as well as patients with oligoclonal juvenile arthritis. Tryptase-positive mast cells were also 38 detected in bone lesions from CRMO patients as well as patients with bacterial osteomyelitis. 39 Taken together, our results identify mast cells as cellular contributors to bone inflammation in 40 CMO/CRMO. Observations of this study promise potential for mast cells and derived 41 mediators as future biomarkers and/or therapeutic targets. 42 43 3
INTRODUCTION

Statistical analysis
When comparing three genotypes, nonparametric Kruskal-Wallis one-way ANOVA, followed by 144 a Dunn's multiple comparison test was used. When comparing two genotypes, the Student's t test 145 was used (GraphPad Software, La Jolla, Calif). All graphs represent mean ± standard deviation. 148 To test the relevance of CTMCs to CMO disease pathophysiology, we collected tail tissues from 149 5 month old wild-type (WT) and Pstpip2 cmo/cmo (CMO) mice, when severe multifocal osteomyelitis 150 develops (3, 16, 43) . Compared to baseline levels of Alcian blue-stained CTMCs in WT tail tissue 151 sections, we observed a trend towards increased CTMCs in CMO tail tissues (Figure 1A, B) . To 152 test for mast cell activation and mediator release, we collected mouse plasma at 5 months of age, 153 and measured the levels of mouse mast cell protease-1 (MCPT1) by ELISA. MCPT1 levels were 154 significantly elevated in plasma from CMO mice, as compared to WT animals ( Figure 1C) . These 155 results suggest that CTMCs are present within inflamed tissues of CMO mice and that mast cell 156 mediators are produced in this autoinflammatory disease model. 157 To test the contribution of CTMCs to the development of CMO disease, we employed a 
Evidence of CTMC activation and role in chronic multifocal osteomyelitis
168
To determine the role of CTMCs in CMO disease onset, cohorts of age-matched CMO and 169 CMO/MC-mice were monitored for early symptoms of CMO, including tail kinks or deformities 170 in hind paws. The CMO/MC-cohort showed a significant delay in disease onset compared to CMO 171 mice, while WT mice showed no disease (Figure 1E, F) . Overall, these results implicate mast 172 cells in promoting inflammation in the CMO model. 186 Previous studies of CMO mice revealed a critical role for elevated IL-1β production and signaling 187 in this model (16, 43) . To test how CTMCs may contribute to the IL-1β production, we prepared 188 tail tissue homogenates from 5 month old WT, CMO and CMO/MC-mice, and measured IL-1β 189 levels by ELISA. Consistent with previous studies (16, 43), CMO tissues had significantly higher 190 IL-1β levels compared to WT mice, but these levels were largely normalized in CMO/MC-mice 191 ( Figure 3A) . Using immunoblot assays to separate the pro-IL-1β and mature IL-1β, we show that 192 CMO/MC-tail tissues had less of the mature form of IL-1β ( Figure 3B) . These results suggest 193 that CTMCs either contribute to IL-1β production in the CMO model, or the recruitment of other 194 immune cells that produce IL-1β in this model.
CTMCs promote IL-1β production and immune cell infiltration in CMO mice
195
Prior studies correlated the severity of CMO with the size of popliteal lymph nodes that "drain" 196 the tail and hind paws (14, 17) . Indeed, popliteal lymph node mass was elevated in CMO mice as To test the potential involvement of mast cells in human CRMO, we screened sera from a 206 previously reported cohort of treatment naïve, newly diagnosed CRMO patients, oligoarticular 207 juvenile arthritis (Oligo JIA) patients, and healthy controls (9). We tested for mast cell chymase 208 by ELISA, and detected very low levels of chymase in 4 of 21 healthy controls, whereas the vast 209 majority of CRMO patients (17 of 20) exhibited detectable serum chymase levels (Figure 5A) . 210 No patients in these cohorts had reported allergies. Of note, a comparable increase in serum 211 12 chymase levels was also observed in Oligo JIA patients (Figure 5A) , which is consistent with a 212 recent study implicating mast cells in arthritis disease models (39).
213
To assess mast cell infiltration to inflamed bone tissue, we performed immunohistochemistry 214 staining of tryptase-positive mast cells in tissue sections from bone biopsies taken from healthy 215 controls (osteotomies), CRMO patients, or bacterial osteomyelitis (OM) patients. While no mast 216 cells were detected in bone biopsies from healthy individuals, we detected mast cells in CRMO 217 lesions, including early CRMO lesions marked by innate immune infiltrates (Figure 5B,C) . 218 Particularly high mast cell counts were detected in chronic CRMO lesions marked by coexisting 219 infiltrates of innate immune cells and lymphocytes (Figure 5B,C) . Mast cell counts were also 220 increased in bacterial OM bone biopsies when compared to controls (Figure 5B,C) . immune cells (14, 16, 21, 22, 43) . In the study presented here, we show that mast cells accumulate 227 in CMO lesions, and promote the accumulation of bone inflammation and lesions. By crossing 228 CMO mice with CTMC-deficient animals (37), we provide evidence for CTMCs promoting CMO 229 disease onset and severity. We also translate these studies to human CRMO, by providing evidence shown). Interestingly, MDSC proliferation has been reported to be mast cell dependent (51).
267
Further studies using more selective tools to deplete and phenotype the inflammatory cells in this 268 model are needed to better define CMO disease pathophysiology.
269
The identity of potential triggers of CMO disease, and restrictions of the phenotypes to certain 270 tissues remains poorly defined. A previous study identified a skewed microbiome in CMO mice 271 that leads to priming of neutrophils to express IL-1β (21). Based on the selective loss of CTMCs 272 in our model, with no effect on mucosal mast cells (37, 42), we have not yet tested the mast cell 273 involvement at the interface with a skewed microbiome. However, future studies using Cpa3 Cre 274 mice, lacking both mucosal and connective tissue mast cells (52), would be an improved model to 275 test the overall contribution of mast cells to this disease.
276
To translate findings from our study on the involvement of mast cells in murine CMO to CRMO 277 in humans, we stained bone samples from CRMO patients and detected increased mast cell 278 populations in CRMO patients. Profiling of CRMO serum biomarkers delivered a number of 279 cytokines and chemokines that were elevated at diagnosis (9), with several of these known to be 280 released by activated human mast cells (53) (54) (55) . Our detection of elevated levels of mast cell 281 chymase in sera from most CRMO patients provides new evidence of mast cell activation in this 282 disease. This was also true for Oligo JIA patient sera, suggesting a common immune mechanism 283 involving mast cells in these diseases. Of note, chymase can directly promote IL-1β production 284 (56), and other mast cell mediators may also contribute to IL-1β-driven disease in CRMO patients 285 (9, 12) . This is also consistent with elevated mast cell density in bone tissue sections from CRMO 286 patients compared to healthy controls that we report in this study. Thus, mast cells may amplify In conclusion, we demonstrate a role for mast cells in the progression of autoinflammatory bone 290 disease using mouse models and human CRMO patient samples. We show that aberrant mast cell 291 activation enhances the cycle of IL-1β-driven sterile inflammation that triggers bone loss in this 292 disease (Figure 6) . Indeed, there is growing evidence of mast cell involvement in 293 autoinflammation in a variety of models and diseases (57). This study provides rationale to study 294 the effects of mast cell-targeted therapies in CRMO and related autoinflammatory bone diseases. Figure 6 
